MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/hc9.0000000000000839

Медицинская библиотека · Hepatology communications · 2025

Abbreviated gadoxetic acid-enhanced MRI versus ultrasonography for HCC surveillance in high-risk patients: A randomized trial protocol.

Park Hyo Jung, Choi Jonggi, Kim Dong Wook, Choi Sang Hyun, Choi Won-Mook, Chung Sung Won, Lee Danbi, Shim Ju Hyun, Lee Han Chu, Lim Young-Suk, Kim Min-Ju, Singal Amit G, Park Seong Ho, Kim So Yeon

СтатьяПротокол клинического исследованияПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

Although ultrasonography (US) is widely recommended for HCC surveillance, its limited sensitivity for early-stage HCC remains a concern. Gadoxetic acid-enhanced abbreviated MRI (HBP-AMRI) has demonstrated high diagnostic performance; however, its role in routine surveillance settings remains uncertain due to limited prospective comparative evidence. The AMRIUS study (Abbreviated MRI using gadoxetic acid versus Ultrasonography for Surveillance of early-stage HCC in high-risk patients) aims to prospectively compare the effectiveness of HBP-AMRI and US for HCC surveillance in high-risk patients with cirrhosis.

METHODS

AMRIUS is a randomized controlled trial (RCT) enrolling 806 high-risk patients with cirrhosis, randomly assigned (1:1) to undergo either biannual HBP-AMRI or US for 2 surveillance rounds. The primary endpoint is the detection rate of early-stage HCC [Barcelona Clinic Liver Cancer (BCLC) stage 0 or A]. Secondary endpoints include false referral rate of BCLC 0 or A HCC, detection and false referral rates for BCLC stage 0 and all-stage HCC, BCLC stage distribution at initial HCC diagnosis, and the rate of curative treatment. Structured imaging protocols and quality assessments will be implemented.

DISCUSSION: AMRIUS is the first RCT designed to provide high-level evidence comparing HBP-AMRI and US for HCC surveillance. Its findings are expected to inform future guidelines and support risk-adapted strategies that prioritize early detection and curative treatment eligibility, particularly for patients likely to benefit from high-sensitivity imaging.

TRIAL REGISTRATION: Registered at Clinical Research Information Service on May 22, 2022 (KCT0007417) and ClinicalTrials.gov on March 9, 2024 (NCT06312826). Participant recruitment began on August 26, 2022. Follow-up is ongoing.

Для цитирования: Park Hyo Jung, Choi Jonggi, Kim Dong Wook, Choi Sang Hyun, Choi Won-Mook, Chung Sung Won, Lee Danbi, Shim Ju Hyun, Lee Han Chu, Lim Young-Suk, Kim Min-Ju, Singal Amit G, Park Seong Ho, Kim So Yeon. Abbreviated gadoxetic acid-enhanced MRI versus ultrasonography for HCC surveillance in high-risk patients: A randomized trial protocol.. Hepatology communications. 2025. DOI: 10.1097/hc9.0000000000000839.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.